RSC Medicinal Chemistry is a pivotal journal in the realm of medicinal chemistry, published by the esteemed Royal Society of Chemistry. With a focus on innovative research that intersects various disciplines such as biochemistry, drug discovery, pharmaceutical science, and organic chemistry, this journal serves as a vital resource for researchers, professionals, and students alike. Its impressive impact factor and notable rankings—positioning it within the Q1 and Q2 quartiles across critical categories—underscore its significance in advancing knowledge and fostering collaboration within the scientific community. RSC Medicinal Chemistry is dedicated to open access, ensuring that cutting-edge findings on drug design and therapeutic applications are freely available to enhance global research efforts. With a commitment to publication excellence from 2020 to 2024, it is a prominent platform where groundbreaking ideas meet practical implications, making it indispensable for anyone committed to the forefront of medicinal advances.

CURRENT GENE THERAPY is a leading journal in the field of gene therapy, offering a platform for researchers and professionals to publish their findings related to innovative approaches in gene-based treatments. Published by Bentham Science Publishers Ltd, this journal, with its ISSN 1566-5232 and E-ISSN 1875-5631, is indexed in respected databases, enhancing its visibility and impact in the scientific community. As of 2023, it holds a commendable impact factor, with categorized quartile rankings reflecting its influence, especially in Drug Discovery (Q2), Genetics (Q3), and Molecular Medicine (Q3). Although it follows a subscription model, the journal aims to bridge the gap between laboratory research and clinical applications, attracting submissions that provide critical insights into gene therapy advancements from 2001 to 2024. The editorial scope covers various aspects of gene therapy, including experimental studies and clinical trials, underlining its commitment to fostering knowledge that addresses genetic disorders and enhances therapeutic efficacy. Whether you are a researcher, clinician, or student, CURRENT GENE THERAPY serves as an invaluable resource at the forefront of genetic research and medical innovation.

DRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.

Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.

NUCLEIC ACIDS RESEARCH, published by Oxford University Press, is a premier peer-reviewed journal in the field of genetics, holding a prestigious Q1 ranking in this domain as of 2023. Since its inception in 1974 and with a converged publication horizon extending to 2024, this journal has established itself as a vital resource for researchers and professionals interested in the molecular aspects of nucleic acids, encompassing DNA and RNA studies as well as their implications in biochemistry and molecular biology. With an impressive Scopus rank of #6 out of 347 in Genetics, this journal is positioned in the 98th percentile among its peers, highlighting its significant impact and relevance in the scientific community. As an open access journal since 2005, NUCLEIC ACIDS RESEARCH ensures wide dissemination of knowledge, promoting collaborative advancements in genetic research. For those looking to stay at the forefront of nucleic acid research, this journal remains an essential publication for accessing cutting-edge findings and innovative methodologies in the field.

CURRENT TOPICS IN MEDICINAL CHEMISTRY is a prestigious journal published by Bentham Science Publishers Ltd, dedicated to advancing the field of medicinal chemistry through the dissemination of high-quality research from 2001 to 2024. With an ISSN of 1568-0266 and an E-ISSN of 1873-4294, this journal is recognized for its significant contributions, as evidenced by its Scopus ranking in the 63rd percentile in the category of Drug Discovery, specifically at position #58 out of 157. Currently placed in Quartile 3 within Drug Discovery and Quartile 2 in miscellaneous medicine as of 2023, it serves as an essential resource for researchers, professionals, and students interested in the latest developments, methodologies, and applications in medicinal chemistry. The journal aims to foster collaboration and innovation by featuring original research articles, reviews, and brief communications that address current and emerging challenges in the discipline. Although it is not an open access platform, the journal's rich content is indispensable for those striving to enhance therapeutic strategies and drug development processes.

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

ANTI-CANCER DRUGS is a leading journal in the domain of cancer research and pharmacology, published by Lippincott Williams & Wilkins. With its inception dating back to 1990 and ongoing publication through 2024, this journal serves as a vital resource for researchers, clinicians, and students interested in the latest advancements and discoveries in cancer therapeutics. Although classified in the Q3 quartile across relevant categories such as Cancer Research and Oncology, its growing impact is evidenced by its competitive Scopus rankings, positioned within the 30th to 52nd percentiles across various disciplines. The journal remains committed to promoting innovative research that can translate into effective anti-cancer strategies, providing valuable insights into drug development and applications. While it does not currently offer open access, the journal continues to attract a sophisticated readership, making it an essential platform for disseminating significant findings in the ever-evolving field of oncology.

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS is a vital academic journal published by Taylor & Francis Inc, dedicated to the intricate and evolving domains of biochemistry, genetics, and molecular medicine. With an ISSN of 1525-7770 and E-ISSN of 1532-2335, this journal aims to provide a comprehensive platform for the dissemination of research findings, reviews, and methodologies related to nucleosides, nucleotides, and nucleic acids. As a research journal thriving since its inception in 2000, it reflects a diverse spectrum of studies crucial for advancing knowledge in biochemistry (ranked Q4) and genetics (Q4), while also achieving Q3 status in medicine (miscellaneous). Despite its current standing in the quartiles and Scopus rankings indicative of an emergent trajectory, the journal retains significant relevance for those delving into interdisciplinary research that intersects these fields. Researchers, professionals, and students alike can explore a plethora of original research articles, thought-provoking reviews, and updates on pioneering advances that shape our understanding of molecular biology. With its unwavering commitment to scholarly excellence, NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS continues to be an essential resource for those aiming to contribute to and stay informed about this pivotal area of scientific inquiry.